Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Thu, 25.01.2024
PNE AG
First Berlin Equity Research hat ein Research Update zu PNE AG (ISIN:
DE000A0JBPG2) veröffentlicht. Analyst Dr. Karsten von Blumenthal bestätigt
seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 22,00.
Zusammenfassung:
PNE hat zum Jahreswechsel zwei deutsche Windparks mit einer Gesamtleistung
von 22 MW in Betrieb genommen. [ … ]
Thu, 25.01.2024
q.beyond AG
One q.beyond to drive margins in 2024e
In light of the ongoing restructuring process as well as macro-headwinds,
we observed a rather uninspiring operating performance, especially on the
bottom-line, as of 9M ‘23. Despite that, q.beyond is seen to achieve its FY
’23 guidance: €185-191m sales, € 5-7m EBITDA and > € [ … ]
Thu, 25.01.2024
MLP SE
Low risk, high reward - added to NuWays' Alpha List
At current levels, MLP’s stock offers a strong upside potential while
potential downside risks seem priced in and should not impact bottom line
significantly. Here is our take:
(1) Strong diversification of negatively correlated business segments
protects MLP against changing macroecon [ … ]
Wed, 24.01.2024
VOQUZ Labs AG
Reassuring order intake and strong trading momentum
Yesterday, VOQUZ published reassuring 2023 order intake figures, pointing
towards improved operations in the second half of the year.
Total order intake increased by 11.5% yoy to € 5.5m with recurring orders
accounting for a solid 58% (€ 3.2m). The share of product related sales
sl [ … ]
Wed, 24.01.2024
NFON AG
Operational turnaround in full swing – Added to Alpha List; chg.
While the company has not been on the radar of most investors due to rather
underwhelming operating performances in recent years, efficiency measures,
which have been imposed lately as well as the reorganization of the topand
C-level management are starting to bear fruit, t [ … ]
Tue, 23.01.2024
Klondike Gold Corp
First Berlin Equity Research hat ein Research Update zu Klondike Gold Corp.
(ISIN: CA4989033010) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von CAD 0,75.
Zusammenfassung:
Klondike Gold veröffentlichte die Bohrergebnisse der Zone Standard, die die
Reihe der auffälligen [ … ]
Tue, 23.01.2024
DEMIRE AG
Annual portfolio revaluation in line with expectations
Yesterday, DEMIRE published an ad-hoc following a draft valuation from
Savills. The external surveyor is currently performing the annual valuation
of DEMIRE’s investment properties as of 31 December ’23. Based on the
draft, the company currently expects that the fair value of th [ … ]
Tue, 23.01.2024
Westwing Group AG
Storytelling-based value and growth play for 2024
With its storytelling-based retail approach and inspiration-driven revenue
generation, Westwing is a unique play on the growing online penetration in
the home and living segment. The latter still stands at 25% for fashion or >35% for electronics. Its focus on
curated home furnishings along wi [ … ]
Mon, 22.01.2024
LION E-Mobility AG
A new CEO to kick off the year
Topic: LION announced to have a singed a highly qualified successor for the
current CEO, which is leaving at the end of January. Following LION‘s major
transformation last year, the company looks poised for strong growth.
At the end of November, LION announced the departure of its CEO Winfried
Buss end of [ … ]
Fri, 19.01.2024
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics (Cardiol) has completed >50% of patient recruitment
for CardiolRx's two lead indications, acute myocarditi [ … ]